Previously we reported that a loss of the cell adhesion molecule, E-cadherin, in ER+, endocrine-sensitive breast cancer cell models resulted in an adverse, invasive response to the endocrine agents tamoxifen and fulvestrant [21]. This evidence concerns the gene ESR1 and breast cancer.